Ranbaxy Laboratories has reported results for the third quarter ended September 30, 2013.
The company has reported a net loss Rs 842.23 crore as compared to a net profit of Rs 552.19 crore in the same quarter previous year. Total income of the company has decreased by 3.74% at Rs 1470.18 crore for quarter under review as compared to Rs 1527.36 crore for the quarter ended September 30, 2012.
On the consolidated basis, the group has reported a net loss after taxes, minority Interest and share of proflt/(loss) of associates at Rs 454.17 crore as compared to a net profit of Rs 754.17 crore in the same quarter previous year. However, total income of the group rose 1.93% to Rs 2827.73 crore for quarter under review as against Rs 2774.23 crore in corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1826.55 |
| Dr. Reddys Lab | 1281.00 |
| Cipla | 1337.40 |
| Zydus Lifesciences | 918.00 |
| Lupin | 2370.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: